VivaCell Biotechnology España announces that it has signed an exclusive, non-transferable, sub-licensable, worldwide patent license agreement with Indena SpA for Ingenol isolation. The patent licensed out to Indena refers to a unique isolation method for isolating Ingenol from natural sources that involves only limited handling of the skin-irritant oils and also produce high yields of this macrocyclic diterpenoid.
Over the past few years there has been considerable interest in Ingenol derivates as biological tools because their potent anticancer and antiviral activity, highlighting the 3-esters semisynthetic derivates such as Ingenol mebutate (ingenol 3-angelate, Picato®, Leo Pharma). Starting from Ingenol, VivaCell has produced a novel derivative, VCE-002, which is in the pipeline of the company.
During the last years, VivaCell has invested approximately 2M € in R&D and holds several international patents. This settlement demonstrates VivaCell's leading patent portfolio and enables the company to focus on further licensing opportunities in the pharmaceutical market.
About Indena SpA
Indena, based in Milano (Italy), is the world leader in the identification, development and production of botanical active ingredients for use in pharmaceutical, health food and cosmetics industries.